Clinical Scorecard: Assessing Brain Atrophy through Visual Evaluation in Structural MRI: Is This Approach Becoming Obsolete?

At a Glance

Key Highlights

• Structural MRI visual rating scales remain recommended for assessing regional brain atrophy despite advances in automated volumetric methods.
• Automated volumetry and machine learning tools show promise but lack sufficient validation in routine clinical practice and are sensitive to MRI acquisition variability.
• The newly proposed Amygdala Atrophy Scale (ASS) demonstrates high reliability and may improve differentiation of neurodegenerative diseases involving amygdala atrophy, such as LATE.

Guideline-Based Recommendations

Diagnosis

• Use structural MRI to detect vascular lesions and regional atrophy to support differential diagnosis of primary neurodegenerative diseases.
• Apply visual rating scales for regional atrophy assessment by experienced readers as per German S3 Practice Guideline on Dementia and other national/international guidelines.

Management

• Integrate MRI findings with clinical and biomarker data to select patients for disease-modifying therapies targeting specific pathologies.

Monitoring & Follow-up

• Visual rating scales have limited sensitivity for subtle or longitudinal atrophy changes; automated volumetry may assist but requires further validation.

Risks

• Automated volumetric tools may be affected by MRI scanner platform and acquisition parameters, limiting their current clinical applicability.
• Visual rating scales have inter-rater variability and may miss subtle or spatially distributed atrophy.

Patient & Prescribing Data

Patients with mild or uncertain cognitive impairment undergoing diagnostic evaluation

Accurate MRI-based atrophy assessment aids in selecting appropriate patients for emerging disease-modifying therapies targeting specific neurodegenerative pathologies.

Clinical Best Practices

• Perform visual rating of regional brain atrophy on structural MRI using validated scales such as the medial temporal lobe atrophy (MTA) scale and the Amygdala Atrophy Scale (ASS).
• Use visual assessment as the primary method in clinical routine until automated volumetric tools are clinically validated and standardized.
• Consider combining visual rating scales to capture different atrophy patterns for improved differential diagnosis (e.g., MTA for hippocampus, ASS for amygdala).
• Interpret visual rating scores in the context of patient age and clinical presentation; future scale refinements may improve age-related adjustments.
• Remain aware of limitations of visual scales including inter-rater variability and limited sensitivity for early or subtle changes.

References

• European public health guidelines on cognitive impairment diagnosis
• German S3 Practice Guideline on Dementia
• Medial Temporal Lobe Atrophy (MTA) scale by Scheltens et al.
• Amygdala Atrophy Scale (ASS) by Pizzini et al.